pharmaphorum Top Stories - 11 November 2024
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
In this week’s top stories, we hear that Alligator Bioscience’s pancreatic cancer drug 'nearly doubles' survival.
Meanwhile, need it be said, Donald Trump claimed comprehensive victory in the US election and is to be the 47th President. We look at the potential impact on US citizens, as well as pharma.
Novo Nordisk abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease trial.
The UK Sudlow Review was also released, damning the state of the country’s health data ecosystem.
And AstraZeneca confirmed its China president had been detained.
All this and more on pharmaphorum.com.
Top Stories
Alligator Bioscience AB has reported updated results with its CD40 agonist mitazalimab as a first-line treatment for advanced pancreatic cancer, a disease with few treatment options.
It is all over bar the shouting win for the US election, with Donald Trump set to claim the Presidency, potentially with the triple whammy of a Republican majority in the Senate, House of Representatives, and popular vote.
领英推荐
诺和诺德 has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.
阿斯利康 has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after confirming he was under investigation last week.
The UK is squandering the vast resource of NHS patient data because too many obstacles are being placed in front of researchers trying to tap into it – holding back medical advances.
Register to join our upcoming webinars:
Enabling site success: Key insights to reducing burden and increasing access Sponsored by Syneos Health - Nov 12 2024, 10am ET / 4pm CET / 3pm GMT.
Decoding physician prescribing behaviour: A data-driven journey Sponsored by PurpleLab - on November 19 2024, 11am EST / 5pm CET / 4pm GMT
The AI effect in pharma commercial strategy: From data to real-time insight & actions Sponsored by Trueblue - Dec 4 2024, 2pm GMT / 3pm CET / 9am EST